Search results
Showing 226 to 240 of 2569 results for methods
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.
This quality standard covers the diagnosis and initial management of ectopic pregnancy and miscarriage in women in their first trimester (up to 13 completed weeks of pregnancy). It includes assessment and diagnosis for women with suspected early pregnancy loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS69Show all sections
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
Four commonly used methods to increase physical activity (PH2)
This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41 Physical activity: brief advice for adults in primary care (2013) PH44 Exercise referral schemes to promote physical activity (2014) PH54
This quality standard covers managing osteoporosis in adults (aged 18 and over), including assessing risk and preventing fragility fractures. It describes high-quality care in priority areas for improvement.
View quality statements for QS149Show all sections
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Awaiting development Reference number: GID-TA10773 Expected publication date: TBC
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development Reference number: GID-TA10604 Expected publication date: TBC
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Awaiting development Reference number: GID-TA10776 Expected publication date: TBC
Awaiting development Reference number: GID-TA10787 Expected publication date: TBC
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Awaiting development Reference number: GID-TA10823 Expected publication date: TBC
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Awaiting development Reference number: GID-TA10867 Expected publication date: TBC
Awaiting development Reference number: GID-TA10896 Expected publication date: TBC
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Awaiting development Reference number: GID-TA10683 Expected publication date: TBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Awaiting development Reference number: GID-TA10684 Expected publication date: TBC